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The Prognostic Significance asγ- Seminoprotein(γ- Sm) andγ- Sm /Prostate Specific Antigen (PSA) 
Ratio in the Prostate Cancer 
KAZUAKI IWABUCHI (Department of Urology, Saitama Medical School, Moroyama, Iruma-gun, Saitama 350-0495, 
Japan)
 The utility of PSA ratio (free/total PSA) in the diagnosis of early-stage prostate cancer is the primary focus 
of our current research into the interrelationships between various prostate cancer markers. In the present 
study I evaluated the clinical significance of cancer markers, namely prostate specific antigen (PSA) and 
gamma-seminoprotein (γ- Sm), as prognostic factors. Levels of PSA andγ- Sm were analyzed in 139 patients 
diagnosed with prostate cancer between January 1989 and December 1998. Levels of PSA andγ- Sm were 
measured using the enzyme immunoassay (EIA) method. The 139 patients were divided into two groups with 
respect to medians of each marker, andγ- Sm/PSA ratio. Differences in survival rates were then compared by the 
Kaplan-Meier method. Among high stage patients, PSA did not represent statistically significant prognostic factors. 
However, significant differences were observed inγ- Sm andγ- Sm/PSA ratios with regard to survival rates and 
relapse-free rates. As a result,γ- Sm/PSA ratio is useful not only as a diagnostic factor, but also as a prognostic factor.
Keywords: prostate cancer, gamma-seminoprotein, prostate specific antigen, free-to-total prostate specific antigen
ratio, cancer marker
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正常値：3.6 ng/ml以下），γ- Smはフィルスタットγ- Sm 












































Stageは  A ･B ･C ･D1･D2 がそれぞれ 7例，16例，
26例，8例，82例であり，Gradeはwell differentiated
adenocarcinomaが21例， moderately differentiated 




－最高値）はPSA（ng/ml）が34.0（1.0 - 4380），γ- Sm
























Table 1. Median (minimum-maximum) value of cancer 
marker and those ratio in each stage
Table 2. The analysis for cancer marker and those ratio 
using univariate analysis (log-rank test)































γ- Sm/PSA比について，χ2値の高い順にγ- Sm 
/PSA比， γ- Sm，Gradeが 有 意 な 因 子 と さ れ た
（Table 6）．また，γ- SmをPSAに変えて行ったところ，
Grade，γ- Sm/PSA比の2者が有意であった．
Table 4. Background of γ-Sm/PSA ratio in Stage D2 patient 
(n＝82)
＊ :median (minimum-maximum) value
※ :Wilcoxon rank-sum test        
※※ :Contingency table (χ2 test)
Table 3. Background of γ-Sm/PSA ratio in all patient (n＝139)
＊ :median (minimum-maximum) value
※ :Wilcoxon rank-sum test        
※※ :Contingency table (χ2 test)
Fig. 1. Survival curves of all patients (n＝139).
(P value:log-rank test)
Fig. 2. Correlation between PSA and γ-Sm in Stage D2



























































Table 7. The relapse free time analyses (log-rank test) 
concerning about cancer marker and those ratio
※:patient lower value survived longer than higher value.
Table 5. Proportional hazards model (multiple variate) in all 
patient (n＝139)
Table 6. Proportional hazards model (multiple variate) in 
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